Denosumab

Denosumab is a fully human monoclonal antibody (IgG2) that targets RANKL (receptor activator of nuclear factor kappa-B ligand), inhibiting osteoclast formation and function to reduce bone resorption. It is used for osteoporosis, bone metastases, and giant cell tumor of bone. Mediocon Inc supplies pharmaceutical-grade Denosumab for bulk pharma manufacturing.

Key Features

• Analgesic, antipyretic & anti-inflammatory
• USP/BP/IP compliant quality
• Widely used in cardiovascular therapy
• Suitable for tablet and effervescent formulations

Applications

• Postmenopausal osteoporosis
• Bone metastases in solid tumors
• Giant cell tumor of bone
• Cancer treatment-induced bone loss

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings